These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1622636)

  • 1. Indications for cytostatic therapy in metastatic breast cancer.
    Kvinnsland S
    Acta Oncol; 1992; 31(2):215-8. PubMed ID: 1622636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of distant metastases in hormone-sensitive breast cancer.
    Rugo HS
    Breast; 2008 Jan; 17 Suppl 1():S3-8. PubMed ID: 18279764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metastatic breast cancer: what are the objectives?].
    Salvini P; Ripa C; Ginanni V
    Tumori; 2000; 86(5 Suppl 1):S22-8. PubMed ID: 11195289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of chemotherapy for metastatic breast cancer.
    Miller KD; Sledge GW
    Hematol Oncol Clin North Am; 1999 Apr; 13(2):415-34. PubMed ID: 10363138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance treatment in metastatic breast cancer.
    Sánchez-Muñoz A; Pérez-Ruiz E; Ribelles N; Márquez A; Alba E
    Expert Rev Anticancer Ther; 2008 Dec; 8(12):1907-12. PubMed ID: 19046111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Respective indications for hormone therapy, induction chemotherapy and adjuvant chemotherapy in breast cancer without clinically discernable distant metastases].
    Roy JA; Piccart MJ
    Rev Med Brux; 1995; 16(4):242-4. PubMed ID: 7481234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of chemotherapy in metastatic breast cancer.
    Garber JE; Henderson IC
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):807-21. PubMed ID: 2481671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in chemotherapy for HER2-negative metastatic breast cancer.
    Mukai H; Ito M
    Chin Clin Oncol; 2018 Jun; 7(3):26. PubMed ID: 30056728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer chemotherapy based on evidence--metastatic breast cancer].
    Takashima S; Saeki T; Ohsumi S
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):44-51. PubMed ID: 10660732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
    Baselga J
    Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New strategies for managing metastatic breast cancer.
    Olin JJ; Muss HB
    Oncology (Williston Park); 2000 May; 14(5):629-41; discussion 642-4, 647-8. PubMed ID: 10853456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
    Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
    Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy in metastasized breast carcinoma].
    Bontenbal M; de Wit R; Klijn JG; Seynaeve C
    Ned Tijdschr Geneeskd; 1998 Jul; 142(30):1709-13. PubMed ID: 9763866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Survival and Cure in Distant Metastatic Breast Cancer.
    Güth U; Elfgen C; Montagna G; Schmid SM
    Oncology; 2019; 97(2):82-93. PubMed ID: 31055570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer.
    Di Leo A; Piccart MJ
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):27-32. PubMed ID: 10403471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of advanced breast cancer.
    Szántó J
    Acta Med Hung; 1994; 50(3-4):185-93. PubMed ID: 8587832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.